Richard Yeh & team Citi

Citi repeats in third place, this time under the sole leadership of Richard Yeh. The three-member team is headquartered in Hong Kong and follows ten stocks, including Tong Ren Tang Technologies Co. The analysts initiated coverage on the Beijing-based pharmaceuticals manufacturer in January with a buy rating, at HK$8.16, largely on the strength of its earnings growth. The stock had shot up 26.2 percent, to HK$10.30, by the end of March — and the researchers remain bullish. “Despite the near-term overhang of government policies, the industry will continue to experience significant growth opportunities, particularly in rural markets,” Yeh believes. “With the aging population and continued government support — such as expansion in health care coverage and improvements in reimbursement — the industry will continue to see impressive compound annual growth in excess of 16 percent in the next three to five years.” Clients are impressed. Yeh “has a solid understanding of the pharmaceutical sector and is a smart stock picker,” asserts one money manager. “He is very hard working and replies to client requests quickly.” — ­Leslie Kramer